Clinical Trials Logo

Clinical Trial Summary

This study is a single-center, open Phase I study, to observe the effectiveness and safety of CT103A combined with different doses of Selinexor in patients with relapsed/refractory extramedullary multiple myeloma, and the pharmacokinetics of Selinexor and CT103A Kinetic and pharmacodynamic characteristics.

Clinical Trial Description

In this study, two dose groups of 20 mg/week and 40 mg/week will be set for Selinexor, and the dose of CT103A is 1.0×106 cells/Kg. Subjects in all dose groups will firstly receive a single dose infusion of CT103A, at least 1 month post infusion and platelet recovery to ≥50×109/L. Then subjects began to take Selinexor once a week for one year. Each dose group level will include 8-10 subjects, and a total of 16-20 subjects are expected to be enrolled. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05201118
Study type Interventional
Source Huazhong University of Science and Technology
Contact Jianfeng Zhou
Phone 86-13627284963
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date February 8, 2022
Completion date December 6, 2023